Investor Relations

Recent Event

Stifel 2019 Healthcare Conference

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2018

Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system conditions. The Company has four novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the acute treatment of migraine, and TRV734 for maintenance treatment of opioid use disorder. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain.

Investor Contact Information

Company

Trevena, Inc.
955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087
T: (610) 354-8840

Investor Relations

KCSA Strategic Communications
Valter Pinto / Allison Soss
T: 212-896-1254 / 212-896-1267
ir@trevena.com